nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

20.06.2019 | Original Article

Diagnostic value of surveillance ¹⁸F-fluorodeoxyglucose PET/CT for detecting recurrent esophageal carcinoma after curative treatment

verfasst von: Soo Jeong Kim, Seung Hyup Hyun, Seung Hwan Moon, Kyung Soo Lee, Jong-Mu Sun, Dongryul Oh, Yong Chan Ahn, Jae Il Zo, Young Mog Shim, Joon Young Choi

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Esophageal carcinoma recurs within two years in approximately half of patients who receive curative treatment and is associated with poor survival. While ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is a reliable method of detecting recurrent esophageal carcinoma, in most previous studies FDG PET/CT scans were performed when recurrence was suspected. The aim of this study was to evaluate FDG PET/CT as a surveillance modality to detect recurrence of esophageal carcinoma after curative treatment where clinical indications of recurrent disease are absent.

Methods

A total of 782 consecutive FDG PET/CT studies from 375 patients with esophageal carcinoma after definitive treatment were reviewed. Abnormal lesions suggestive of recurrence on PET/CT scans were then evaluated. Recurrence was determined by pathologic confirmation or other clinical evidence within two months of the scan. If no clinical evidence for recurrence was found at least 6 months after the scan, the case was considered a true negative for recurrence.

Results

The diagnostic sensitivity and specificity of PET/CT for detecting recurrent esophageal carcinomas were 100% (64/64) and 94.0% (675/718), respectively. There were no significant differences in the diagnostic performance of PET/CT for detecting recurrence according to initial stage or time between PET/CT and curative treatments. Unexpected second primary cancers were detected by FDG PET/CT in seven patients.

Conclusions

Surveillance FDG PET/CT is a useful imaging tool for detection of early recurrence or clinically unsuspected early second primary cancer in patients with curatively treated esophageal carcinoma but without clinical suspicion of recurrence.

Mariette C, Balon JM, Piessen G, Fabre S, Van Seuningen I, Triboulet JP. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer. 2003;97(7):1616–23. https://doi.org/10.1002/cncr.11228.CrossRefPubMed

Blom RL, Lagarde SM, van Oudenaarde K, Klinkenbijl JH, Hulshof MC, van Laarhoven HW, et al. Survival after recurrent esophageal carcinoma has not improved over the past 18 years. Ann Surg Oncol. 2013;20(8):2693–8. https://doi.org/10.1245/s10434-013-2936-3.CrossRefPubMed

Hamai Y, Hihara J, Emi M, Furukawa T, Ibuki Y, Yamakita I, et al. Treatment outcomes and prognostic factors after recurrence of esophageal squamous cell carcinoma. World J Surg. 2018;42(7):2190-2198. https://doi.org/10.1007/s00268-017-4430-8.

Yamashita K, Watanabe M, Mine S, Kurogochi T, Okamura A, Hayami M, et al. Patterns and outcomes of recurrent esophageal cancer after curative esophagectomy. World J Surg. 2017;41(9):2337–44. https://doi.org/10.1007/s00268-017-4024-5.CrossRefPubMed

Schizas D, Lazaridis II, Moris D, Mastoraki A, Lazaridis LD, Tsilimigras DI, et al. The role of surgical treatment in isolated organ recurrence of esophageal cancer-a systematic review of the literature. World J Surg Oncol. 2018;16(1):55. https://doi.org/10.1186/s12957-018-1357-y.CrossRefPubMedPubMedCentral

Zhou YQ, Ding NX, Wang LJ, Liu W, Jiang M, Lu JC. Salvage radiochemotherapy for lymph node recurrence after radical surgery of esophageal cancer. Medicine. 2018;97(5):e9777. https://doi.org/10.1097/md.0000000000009777.CrossRefPubMedPubMedCentral

Ajani JA, D’Amico TA, Almhanna K, Bentrem DJ, Besh S, Chao J, et al. Esophageal and esophagogastric junction cancers, version 1. 2015. Journal of the National Comprehensive Cancer Network : JNCCN. 2015;13(2):194–227.CrossRefPubMed

Nakagawa S, Kanda T, Kosugi S, Ohashi M, Suzuki T, Hatakeyama K. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg. 2004;198(2):205–11. https://doi.org/10.1016/j.jamcollsurg.2003.10.005.CrossRefPubMed

Lee SJ, Lee KS, Yim YJ, Kim TS, Shim YM, Kim K. Recurrence of squamous cell carcinoma of the oesophagus after curative surgery: rates and patterns on imaging studies correlated with tumour location and pathological stage. Clin Radiol. 2005;60(5):547–54. https://doi.org/10.1016/j.crad.2004.09.002.CrossRefPubMed

10.

Goense L, van Rossum PS, Reitsma JB, Lam MG, Meijer GJ, van Vulpen M, et al. Diagnostic performance of (18)F-FDG PET and PET/CT for the detection of recurrent esophageal cancer after treatment with curative intent: a systematic review and meta-analysis. J Nucl Med. 2015;56(7):995–1002. https://doi.org/10.2967/jnumed.115.155580.CrossRefPubMed

11.

Choi SH, Kim YT, Kim SK, Kang KW, Goo JM, Kang CH, et al. Positron emission tomography-computed tomography for postoperative surveillance in non-small cell lung cancer. Ann Thorac Surg. 2011;92(5):1826–32. discussion 32. https://doi.org/10.1016/j.athoracsur.2011.07.005.CrossRefPubMed

12.

Marcus C, Paidpally V, Antoniou A, Zaheer A, Wahl RL, Subramaniam RM. ¹⁸F-FDG PET/CT and lung cancer: value of fourth and subsequent posttherapy follow-up scans for patient management. J Nucl Med. 2015;56(2):204–8. https://doi.org/10.2967/jnumed.114.147884.CrossRefPubMed

13.

Dunsky KA, Wehrmann DJ, Osman MM, Thornberry BM, Varvares MA. PET-CT and the detection of the asymptomatic recurrence or second primary lesions in the treated head and neck cancer patient. Laryngoscope. 2013;123(9):2161–4. https://doi.org/10.1002/lary.23941.CrossRefPubMed

14.

Brooks RA, Rader JS, Dehdashti F, Mutch DG, Powell MA, Thaker PH, et al. Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. Gynecol Oncol. 2009;112(1):104–9. https://doi.org/10.1016/j.ygyno.2008.08.028.CrossRefPubMed

15.

Madu MF, Timmerman P, Wouters M, van der Hiel B, van der Hage JA, van Akkooi ACJ. PET/CT surveillance detects asymptomatic recurrences in stage IIIB and IIIC melanoma patients: a prospective cohort study. Melanoma Res. 2017;27(3):251–7. https://doi.org/10.1097/CMR.0000000000000347.CrossRefPubMed

16.

Lee JW, Lee SM, Son MW, Lee MS. Diagnostic performance of FDG PET/CT for surveillance in asymptomatic gastric cancer patients after curative surgical resection. Eur J Nucl Med Mol Imaging. 2016;43(5):881–8. https://doi.org/10.1007/s00259-015-3249-5.CrossRefPubMed

17.

Suh YS, Han DS, Kong SH, Lee HJ, Kim YT, Kim WH, et al. Should adenocarcinoma of the esophagogastric junction be classified as esophageal cancer? A comparative analysis according to the seventh AJCC TNM classification. Ann Surg. 2012;255(5):908–15. https://doi.org/10.1097/SLA.0b013e31824beb95.CrossRefPubMed

18.

Choi JY, Jang HJ, Shim YM, Kim K, Lee KS, Lee KH, et al. ¹⁸F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications. J Nucl Med. 2004;45(11):1843–50.PubMed

19.

Betancourt Cuellar SL, Palacio DP, Wu CC, Carter BW, Correa AM, Hofstetter WL, et al. (18)FDG-PET/CT is useful in the follow-up of surgically treated patients with oesophageal adenocarcinoma. Br J Radiol. 2018;91(1082):20170341. https://doi.org/10.1259/bjr.20170341.CrossRefPubMedPubMedCentral

20.

Mariette C, Taillier G, Van Seuningen I, Triboulet JP. Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma. Ann Thorac Surg. 2004;78(4):1177–83. https://doi.org/10.1016/j.athoracsur.2004.02.068.CrossRefPubMed

21.

Teyton P, Metges JP, Atmani A, Jestin-Le Tallec V, Volant A, Visvikis D, et al. Use of positron emission tomography in surgery follow-up of esophageal cancer. J Gastrointest Surg. 2009;13(3):451–8. https://doi.org/10.1007/s11605-008-0749-7.CrossRefPubMed

22.

Lou F, Sima CS, Adusumilli PS, Bains MS, Sarkaria IS, Rusch VW, et al. Esophageal cancer recurrence patterns and implications for surveillance. J Thorac Oncol. 2013;8(12):1558–62. https://doi.org/10.1097/01.JTO.0000437420.38972.fb.CrossRefPubMedPubMedCentral

23.

Yamaguchi T, Kato K, Nagashima K, Iwasa S, Honma Y, Takashima A, et al. Type of second primary malignancy after achieving complete response by definitive chemoradiation therapy in patients with esophageal squamous cell carcinoma. Int J Clin Oncol. 2018;23(4):652-658. https://doi.org/10.1007/s10147-018-1258-7.

24.

Roh JL, Park JP, Kim JS, Lee JH, Cho KJ, Choi SH, et al. ¹⁸F fluorodeoxyglucose PET/CT in head and neck squamous cell carcinoma with negative neck palpation findings: a prospective study. Radiology. 2014;271(1):153–61. https://doi.org/10.1148/radiol.13131470.CrossRefPubMed

25.

Choi JY, Lee KS, Kwon OJ, Shim YM, Baek CH, Park K, et al. Improved detection of second primary cancer using integrated [¹⁸F] fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging. J Clin Oncol. 2005;23(30):7654–9. https://doi.org/10.1200/JCO.2005.01.4340.CrossRefPubMed

Titel: Diagnostic value of surveillance 18F-fluorodeoxyglucose PET/CT for detecting recurrent esophageal carcinoma after curative treatment
verfasst von: Soo Jeong Kim
Seung Hyup Hyun
Seung Hwan Moon
Kyung Soo Lee
Jong-Mu Sun
Dongryul Oh
Yong Chan Ahn
Jae Il Zo
Young Mog Shim
Joon Young Choi
Publikationsdatum: 20.06.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 9/2019
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-019-04387-4

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Diagnostic value of surveillance ¹⁸F-fluorodeoxyglucose PET/CT for detecting recurrent esophageal carcinoma after curative treatment

Abstract

Purpose

Methods

Results

Conclusions

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2019

Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer

Head-to-head comparison of 11C-PBR28 and 11C-ER176 for quantification of the translocator protein in the human brain

Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma

Synthesis and in vivo evaluation of [18F]UCB-J for PET imaging of synaptic vesicle glycoprotein 2A (SV2A)

Imaging of coronary flow capacity: is there a role for dynamic CT perfusion imaging?

Increase of precuneus metabolism correlates with reduction of PTSD symptoms after EMDR therapy in military veterans: an 18F-FDG PET study during virtual reality exposure to war